Intraperitoneal ropivacaine for post-operative pain following laparoscopic tubal ligation: a randomised double-blind placebo-controlled trial

Jerilee Mariam Khong Azhary1,2,*, Aizura Syafinaz Adlan1,*, Sivakumar S. Balakrishnan1, Siti Rohayu Kamarul Baharain1, Syeda Nureena Syed Jafer Hussain Zaidi1, Nuguelis Razali2, Mukhri Hamdan2, Noor Azmi Mat Adenan2, Siti Zawiah Omar2

1 Department of Obstetrics and Gynecology, Penang General Hospital, Jalan Residensi, 10990 George Town, Pulau Pinang, Malaysia
2 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
*Correspondence: jag23k@yahoo.com (Jerilee Mariam Khong Azhary); aizuraadlan@gmail.com (Aizura Syafinaz Adlan)

DOI: 10.31083/j.ceog.2021.03.2476

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Submitted: 17 January 2021 Revised: 7 March 2021 Accepted: 18 March 2021 Published: 15 June 2021

Background: Female sterilisation is the most common method of contraception worldwide and laparoscopic tubal sterilisation is increasingly considered as a day-surgery procedure. Therefore, pain following this procedure should be seriously addressed. Instillation of 200 to 300 mg of ropivacaine intraperitoneally has been proven effective in controlling pain after laparoscopic tubal ligation (LTL). However, extreme caution must be taken as potential serum toxicity has been reported with the instillation of 150 mg of intraperitoneal ropivacaine. In search of the lowest, most effective dose, this study aimed to evaluate the effectiveness of 112.5 mg of intraperitoneal ropivacaine in reducing post-operative pain after LTL.

Methods: This double-blind, placebo-controlled randomised trial was conducted in an ambulatory care centre in Malaysia. Sixty-two patients scheduled for LTL were recruited. Two patients were excluded from the trial because of intraoperative complications. Sixty patients were randomised to either the placebo group (intraperitoneal normal saline, n = 30) or the ropivacaine group (intraperitoneal ropivacaine, n = 30). Pain scores (using a visual analogue score), and the need for additional analgesia were assessed at 15, 60, 120, and 240 minutes post-LTL. Results: We observed no significant differences in pain scores or the need for additional analgesia between the groups. Conclusion: 112.5 mg of ropivacaine administered intraperitoneally is not more effective than normal saline in decreasing post-operative pain after LTL.

Keywords
Intraperitoneal analgesia; Laparoscopic tubal ligation; Post-operative pain; Ropivacaine

1. Introduction

Laparoscopic tubal sterilisation is increasingly considered as a day-surgery procedure. After careful selection, patients undergoing day-surgery laparoscopic procedures may benefit from early mobilisation, earlier discharge, and reduced analgesia needs [1–6]. Despite such advantages, 35–85% of patients still experience severe post-operative pain after laparoscopic procedures [7], although it may not be comparable to the pain experienced following conventional laparotomy [8, 9].

Tubal ligation pain may originate from the ischemic pressure applied to the tubes and/or the prostaglandin release from the fallopian tube tissues [10, 11]. Further, the tubal spasm from laparoscopic tubal ligation (LTL) can produce more pain than that from diagnostic scopes [12]. Besides tissue trauma, laparoscopic procedure itself can lead to pain due to the effect of carbon dioxide (CO₂) on the peritoneum and diaphragmatic nerves, in addition to visceral ligament traction [7]. Since female sterilisation is the most common method of contraception worldwide [13], pain following this procedure should be seriously addressed, as it may complicate post-operative recovery [14].

The advantages of intraperitoneal analgesia are clinically proven [15–18]. In fact, one of the eleven strategies described by Sou et al. [7] to reduce pain after gynaecological laparoscopic surgery included intraperitoneal analgesia. Examples of some intraperitoneally used local analgesics are lignocaine [19, 20], bupivacaine [21] meperidine [22], and recently, ropivacaine [23–27]. The latter has demonstrated a superior cardioprotective effect compared to bupivacaine [28–30], while providing longer pain relief and reducing opioid usage [31–33]. However, the regular use of intraperitoneal ropivacaine during LTL remains debatable. Significant improvement in pain scores have been shown with the intraperitoneal instillation of 200 mg [25] and 150 mg [26] ropivacaine during LTL. Extreme caution must be taken as potential serum toxicity has been reported with the instillation of 150 mg ropivacaine intraperitoneally [34]. On the contrary, nebulizing a lower dose (100 mg) of ropivacaine intraperitoneally during laparoscopic gynaecological procedures has shown no improvement in the post-operative pain score [27]. While no clinical toxicity was reported with the instillation of ropivacaine between 100 and 300 mg [35], given the rapid absorption of intraperitoneal analgesia, there is an ongoing discussion surrounding the ideal dose of ropivacaine [36] to prevent...
systemic toxicity. Based on these findings, we aimed to investigate the intraperitoneal analgesic effects of ropivacaine at a dose in the range of 100 to 150 mg. In this trial, we administered 112.5 mg of ropivacaine intraperitoneally to reduce post-operative pain after LTL.

2. Materials and methods

2.1 Setting and participants

This study was conducted in the ambulatory care centre of Penang General Hospital, Malaysia. Written informed consent was obtained during patients’ visits to the gynaecology clinic a few weeks before the date of surgery. Women who were assigned an American Society of Anaesthesiologists’ (ASA) physical classification of I or II, aged between 18 and 55 years, and were scheduled to undergo LTL were considered eligible for participation. Patients with known drug allergies to substances in the local anaesthesia, ropivacaine, parecoxib, or having received analgesia 12 hours before the scheduled procedure were excluded. This study was registered and approved by the Ministry of Health Research and Ethics Committee (MREC) of the National Medical Research Register and the Clinical Research Centre (NMRR), Malaysia (NMRR-09-601-3897).

2.2 Randomisation and blinding

As shown in Fig. 1, eligible and consenting patients were randomised and allocated, on completion of their LTL, to either the ropivacaine or the placebo (normal saline) group. Group randomisation was performed according to a table of random numbers. The results were sealed in opaque envelopes and revealed after induction. Except for the research assistant, who prepared the drugs in a different room, all other medical staff, including the surgeon, and the technical staff in charge on the day of the surgery were blinded to the treatment group.

2.3 Intervention

A standard preoperative form was completed in accordance with the Department of Anaesthesia’s protocol. All laparoscopies were performed in the ambulatory care centre’s operation theatre at Penang General Hospital. No premedication or any form of analgesia was administered prior to the procedure. The standard anaesthetic agents used included propofol (1.5–2.5 mg/kg), fentanyl (1–2 mcg/kg), metoclopramide (10 mg), and atracurium (0.3–0.6 mg/kg). Anaesthesia was maintained with 50% nitric oxide, 50% oxygen, and 1–2% sevoflurane. No other analgesic was administered intraproactively.

For each laparoscopy, while the patient was in supine position, a sub-umbilical incision was performed and 2.5 L of CO₂ insufflated into the peritoneal cavity. A 5-mm port was inserted sub-umbically, and pneumoperitoneum was created using a Veress needle. Another 5-mm port was inserted into the right iliac fossa, left iliac fossa, or suprapubic region under direct vision. The ligation of both fallopian tubes was performed with Filshie clips or Fallope rings. At the end of the procedure, before the removal of the laparoscopic port, 15 mL of 0.75% ropivacaine or normal saline was splashed (7.5 mL on each tube) on both ligated tubes under direct vision, as illustrated in Fig. 2.

The abdomen was then deflated, and the 5-mm port was removed under direct vision. The skin was opposed using a subcuticular technique with absorbable sutures. The skin at both port sites was infiltrated with the remaining 5 mL of ropivacaine 0.75% in both groups, following the standard analgesia regimen. Reversal of neuromuscular blockade was achieved with atropine (20 µg/kg) and neostigmine (50 µg/kg). After extubation, the patient received 40% oxygen by mask until reaching full consciousness.

2.4 Post-operative management

Post anaesthesia, the patient was observed in the post-anaesthesia care unit (PACU). Each patient informed the medical staff in charge, who was blinded to the treatment group, of their pain severity using a visual analogue score between 0 and 10 (0 being no pain and 10 being the most severe pain) at 15, 60, 120, and 240 minutes after arrival to the PACU. Medical staff also assessed the need for additional pain relief (intravenous parecoxib 40 mg). After 4 hours post-procedure, the patient’s suitability for discharge was assessed according to the standard local protocol.

2.5 Sample size and statistical analysis

In this study, the sample size calculation was performed by referring to a previous study [25]. The mean pain score at two hours post LTL in the ropivacaine group was 2.03 and that of the control group was 0.97. Assuming that the standard deviation is 1.4, with a two-sided significance level of 5% and power of 80%, the minimum number needed for each group was 30.

Statistical analysis was performed using standard parametric and non-parametric statistics with JMP Pro 14.1 (SAS Institute Inc., Cary, NC, USA). Data are expressed as mean ± standard deviation or number (%). Fisher’s exact test was used to analyse categorical variables, and the independent sample t-test or Mann-Whitney test was used to analyse continuous variables. A two-sided P-value < 0.05 was considered as the threshold for significance.

3. Results

Seventy-four patients were invited to participate in this study during their gynaecological visits. Among them, nine declined to participate and three were found ineligible. At the beginning of the study, 62 patients agreed to participate and provided consent for LTL. However, two patients were excluded from the placebo (n = 1) and ropivacaine groups (n = 1) because of intraoperative complications (severe adhesions requiring extended general anaesthesia and port entry failure requiring conversion to a mini-laparotomy, respectively). Therefore, 60 patients received their allocated treatments. The placebo group (n = 30) received 15 mL of normal saline intraperitoneally, and the ropivacaine group (n = 30) received...
an instillation of 15 mL of 0.75% ropivacaine (equivalent to 112.5 mg). The characteristics of all patients are shown in Table 1. There were no significant differences between groups in terms of age, parity, number of miscarriages, or previous surgeries.

We found no significant differences in the patients’ pain scores between the placebo and the ropivacaine groups at 15, 60, 120, and 240 minutes ($P > 0.05$) after LTL. As shown in Fig. 3, patients randomised to the placebo group documented a mean pain score of 4.14 (standard deviation 2.61) at 15 minutes while the patients from the ropivacaine group scored 3.9 (standard deviation 2.09) [95% confidence interval $-$0.99 to 1.47; $P = 0.70$]. At 60 minutes, patients from the placebo group scored 3.33 (standard deviation 2.28) and the patients assigned to the ropivacaine group provided a pain score of 3.13 (standard deviation 1.87) [95% confidence interval $-$0.88 to 1.28; $P = 0.71$]. At 120 minutes, pain scores of 2.79 (standard deviation 1.40) and 2.23 (standard deviation 1.21) were recorded from patients in the placebo and ropivacaine group, respectively [95% confidence interval $-$0.16 to 1.27; $P = 0.13$]. Patients assigned to the placebo group recorded a pain score of 2.78 (standard deviation 1.86) at 240 minutes, and patients in the ropivacaine group scored 2.1 (standard deviation 1.48) [95% confidence interval $-$0.34 to 1.72; $P = 0.19$]. The need for additional analgesia in the form of intravenous parecoxib was also not statistically different ($P = 0.68$) between the groups. Three patients from each group required additional analgesia at 15 minutes after LTL. At 60 minutes postoperatively, two patients from each group requested additional analgesia. The need for additional analgesia at 120 post LTL was recorded in 5 patients from the placebo group and 2 from the ropivacaine group. No patient requested additional analgesia after 4 hours post-procedure. Pain was reported in the shoulder tip in 13 pa-
Table 1. Demographic data and descriptions of patients undergoing laparoscopic tubal ligation.

|                        | Placebo (n = 30) | Ropivacaine (n = 30) | P-value |
|------------------------|------------------|----------------------|---------|
| Age group (years), n (%) |                  |                      |         |
| 19–25                  | 1 (3.3%)         | 0                    | 0.08    |
| 31–35                  | 13 (43.3%)       | 11 (36.7%)           |         |
| 36–40                  | 9 (30%)          | 8 (26.7%)            |         |
| >41                    | 7 (23.3%)        | 11 (36.7%)           |         |
| Parity, median (IQR)   | 4 (4–5)          | 4 (2–5)              | 0.77    |
| Number of miscarriages, median (IQR) | 1 (1–2) | 2 (1–3) | 0.33 |
| Previous abdominal surgery n (%) |              |                      |         |
| No previous surgery    | 27 (90%)         | 22 (73.3%)           | 0.28    |
| Pfannenstiel           | 1 (3.3%)         | 4 (13.3%)            |         |
| Lanz                   | 2 (6.7%)         | 2 (6.7%)             |         |
| Others                 | 0                | 1 (3.3%)             |         |
| Missing data           | 0                | 1 (3.3%)             |         |

Table 2. Description of post-operative pain according to the treatment groups.

|                        | Placebo (n) | Ropivacaine (n) | P-value |
|------------------------|-------------|-----------------|---------|
| Shoulder tip pain      | 7 (23%)     | 6 (20%)         | 1.00    |
| Port incision site pain| 10 (33%)   | 12 (40%)        | 0.79    |
| Generalised abdominal pain | 9 (30%) | 7 (23%) | 0.77 |
| Non-specific pain      | 4 (1.3%)    | 5 (1.6%)        | 1.00    |

Data are shown in n (%). Significance test was determined using Fisher’s exact test.

Fig. 2. Illustration of intraperitoneal ropivacaine splashing on the ligated tubes during laparoscopic tubal ligation.

Fig. 3. Mean visual analogue scores for pain at 15, 60, 120 and 240 minutes after laparoscopic tubal ligation. Data are shown in mean (standard deviation). Significant test was done with independent sample t-test.

4. Discussion

This randomised placebo-controlled trial showed that intraperitoneal instillation of 112.5 mg of ropivacaine over the ligated tubes during LTL did not significantly improve the post-operative pain score.

The pain-relief mechanisms mediated by intraperitoneal local analgesia are unclear, but the blockage of free afferent
nerve endings in the peritoneum could play a potential role [35]. However, the effectiveness of intraperitoneal local analgesia varies with the procedure [17]. Despite there being six times more randomised controlled trials in laparoscopic cholecystectomy, the evidence for intraperitoneal local analgesia during gynaecological and gastric laparoscopy appears to be stronger [18]. Unfortunately, the available data from trials focusing on pain relief after LTL were not only scarce but also conflicting in nature [19, 22, 24, 25, 37, 38]. For example, intraperitoneal analgesia, whether alone or in combination with other local analgesia, was found to be an effective and safe method to manage post-operative pain after LTL in some reports [19, 22, 25, 37], while others have found no benefit from this route [24, 38]. A reason for the failure of intraperitoneal local analgesia to reduce post-operative pain could be that these local analgesics may work better for local incisional pain rather than for visceral pain [39].

In the present study, intraperitoneal administration of 112.5 mg of ropivacaine did not improve the pain score between 15 minutes and 2 hours post-operatively. However, a possible significant improvement may have been possible 2 hours post-LTL. In a recent systematic review and meta-analysis of instilled intraperitoneal ropivacaine during laparoscopic cholecystectomy, concentrations as low as 0.25–1.5% were reported to lead to a significant reduction in the pain score measured with visual analogue pain score between 6–9 and 9–24 hours post-operatively [40]. The selected time point to assess pain was six hours, a reflection of the long-lasting effects of local analgesia [41]. Unfortunately, it was not possible to observe our patients beyond six hours as the local protocol guideline advises allowance of discharge within four hours after uncomplicated day-surgery LTL procedures. Moreover, pain management during pelvic laparoscopy was supposedly to be more successful than that during laparoscopic cholecystectomy [9]. The negative outcome of intraperitoneal instillation from our trial could also be attributed to the time of intraperitoneal local anaesthetic instillation. Although there is inadequate evidence to conclusively determine the best timing to instill local analgesia intraperitoneally [42], some studies have observed a successful pain control when local analgesia is applied before tissue trauma [43, 44] rather than at the end of the surgery. Finally, we acknowledge that the dose of ropivacaine and/or the sample size may have been inadequate to produce a significant effect between 15 minutes and 4 hours post-operatively. The administered dose was selected based on two reasons. We chose 112.5 mg not only to facilitate drug preparation (15 mL of 0.75% ropivacaine and 5 mL of 0.75% ropivacaine under port side skin incision), but also because Labaille et al. [34] reported potential serum toxicity in 2 out of 19 patients with 150 mg of intraperitoneal ropivacaine, although clinical toxicity was not observed. Though a significant reduction in pain score after LTL was observed with the intraperitoneal administration of 150–200 mg of ropivacaine [25, 26], care must be taken before administering higher doses. Therefore, further trials are required to determine the safest, most effective, and lowest dose of intraperitoneal ropivacaine to reduce pain after LTL.

5. Conclusions
This randomised placebo-controlled trial showed that instillation of 112.5 mg of ropivacaine intraperitoneally during LTL did not significantly improve the post-operative pain score. However, further research is needed to confirm whether the dose of ropivacaine used and the observation time were appropriate.

Abbreviations
ASA, American Society of Anesthesiologist; LTL, laparoscopic tubal ligation; PACU, Post-Anesthesia Care Unit.

Author contributions
JMKA, ASA, NAMA and SZO conceived and designed the experiments. JMKA, SSB, SRKB, performed the experiments. JMKA, SNSJHZ, NR and MH analyzed the data. SSB, SRKB, SNSJHZ, NR and NAMA contributed reagents and materials. JMKA, ASA, MH and SZO wrote the paper.

Ethics approval and consent to participate
Written informed consent was obtained from all participants. This study was registered and approved by the Ministry of Health Research and Ethics Committee (MREC) of the National Medical Research Register and the Clinical Research Centre (NMRR), Malaysia (NMRR-09-601-3897).

Acknowledgment
The authors would like to thank all the patients that participated in this study, the health care professionals, and staff from the Department of Anaesthesia and the Department of Obstetrics and Gynaecology, Penang General Hospital, Malaysia. We thank Miyuki Harada of the Department of Obstetrics and Gynaecology, University of Tokyo, for her valuable comments. We would also like to thank Carolyn Yim Cheu Wai of the Department of Anesthesia and Abqariyah Binti Yahya @ Ahmad Noor of the Department of Social and Preventive Medicine, University Malaya for their expert comment and statistical calculation.

Funding
This research received no external funding.

Conflict of interest
The authors declare no conflict of interest.

References
[1] Psaila J, Agrawal S, Fountain U, Whitfield T, Murgatroyd B, Dunsmire MF, et al. Day-surgery laparoscopic cholecystectomy: factors influencing same-day discharge. World Journal of Surgery. 2008; 32: 76–81.
[2] Vuilleumier H, Halkic N. Laparoscopic cholecystectomy as a day surgery procedure: implementation and audit of 136 consecutive...
cases in a university hospital. World Journal of Surgery. 2004; 28: 737–740.

[3] Wen KC, Sung PL, Chang WH, Horng HC, Chen YJ, Lee WL, et al. A case-control study to compare the outcome of women treated by two minimally invasive procedures-ultraminilaparotomy, myomeotomy and laparoscopic myoectomy. Taiwanese Journal of Obstetrics and Gynecology. 2018; 57: 264–269.

[4] Wen KC, Chen YJ, Sung PL, Wang PH. Comparing uterine fibroids treated by myomeotomy through traditional laparotomy and 2 modified approaches: ultraminilaparotomy and laparoscopically assisted ultraminilaparotomy. American Journal of Obstetrics and Gynecology. 2010; 202: 144.e1–144.e8.

[5] Lee WL, Liu WM, Cheng MH, Chao HT, Fuh JL, Wang PH. Uterine vascular occlusion in management of leiomyomas: laparoscopy vs laparotomy. Journal of Minimally Invasive Gynecology. 2009; 16: 562–568.

[6] Wang PH, Liu WM, Fuh JL, Chao HT, Yuan CC, Chao KC. Symptomatic myoma treated with laparoscopic uterine vessel occlusion and subsequent immediate myomectomy: which is the optimal surgical approach? Fertility and Sterility. 2009; 92: 762–769.

[7] Sato CH, Chan-Tiopiano M, Chung KC, Chen YJ, Horng HC, Lee WL, et al. Pain after laparoscopic surgery: Focus on shoulder-tip pain after gynecological laparoscopic surgery. Journal of the Chinese Medical Association. 2019; 82: 819–826.

[8] Tobias JD. Pain management following laparoscopy: can we do better? Saudi Journal of Anaesthesia. 2013; 7: 3–4.

[9] Alexander JI. Pain after laparoscopy. British Journal of Anaesthesia. 1997; 79: 369–378.

[10] Brodie BL, Casper RF. Prostaglandins mediate post-operative pain in Falope ring sterilisation. American Journal of Obstetrics and Gynecology. 1985; 151: 175–177.

[11] Ogra SS, Kirton KT, Tomasi TB Jr, Lippes J. Prostaglandins in the human fallopian tube. Fertility and Sterility. 1974; 25: 250–255.

[12] Davis A, Millar JM. Postoperative pain: a comparison of laparoscopic sterilisation and diagnostic laparoscopy. Anaesthesia. 1988; 43: 796–797.

[13] United Nations. Population division. Department of Economic and Social Affairs. World Contraceptive Pattern. 2013.

[14] Power I, Barratt S. Analgesic agents for the postoperative period. Nonopioids. The Surgical Clinics of North America. 1999; 79: 275–295.

[15] Gupta A. Local anaesthesia for pain relief after laparoscopic cholecystectomy—a systematic review. Best Practice & Research. Clinical Anaesthesiology. 2005; 19: 275–292.

[16] Boddy AP, Mehta S, Rhodes M. The effect of intraperitoneal local anaesthesia in laparoscopic cholecystectomy: a systematic review and meta-analysis. Anaesthesia and Anaesthesia. 2006; 103: 682–688.

[17] Meinich S, Jørgensen H, Weterslev J, Dahl JB. Local anesthetic infiltration for postoperative pain relief after laparoscopic cholecystectomy: a qualitative and quantitative systematic review of intraperitoneal, post-site infiltration and mesosalpinx block. Anaesthesia and Anaesthesia. 2000; 90: 899–912.

[18] Hamill JK, Rahiri J, Hill AG. Analgesic effect of intraperitoneal local anesthetic in surgery: an overview of systematic reviews. Journal of Surgical Research. 2017; 212: 167–177.

[19] Manjunath AP, Chhabra N, Girija S, Nair S. Pain relief in laparoscopic tubal ligation using intraperitoneal lignocaine: a double-masked randomised controlled trial. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2012; 163: 110–114.

[20] Ram D, Sista SC, Karthikeyan VS, Ali SM, Badhe AS, Mahakshmy T. Comparison of intravenous and intraperitoneal lignocaine for pain relief following laparoscopic cholecystectomy: a double-blind, randomised, clinical trial. Surgical Endoscopy. 2014; 28: 1291–1297.

[21] Butala BP, Shah VR, Nived K. Randomised double-blind trial of intraperitoneal instillation of bupivacaine and morphine for pain relief after laparoscopic gynecological surgeries. Saudi Journal of Anaesthesia. 2013; 7: 18–23.

[22] Colbert ST, Moran K, O’Hanlon DM, Chambers F, Moriarty DC, Blunnie WP. An assessment of the value of intraperitoneal meperidine for analgesia postlaparoscopic tubal ligation. Anaesthesia and Anaesthesia. 2000; 91: 667–670.

[23] Bindra TK, Kumar P, Rani P, Kumar A, Bariar H. Preemptive analgesia by intraperitoneal instillation of ropivacaine in laparoscopic. Anaesthesia, Essays, and Researches. 2017; 11: 740–744.

[24] Kaufman Y, Ostrovsky L, Klein O, Hirsh I, Auslander R, Pizov R, et al. Pain reduction by continuous intraperitoneal of ropivacaine during gynaecological laparoscopic surgery. Gynecological Surgery. 2013; 10: 51–56.

[25] Dreher JK, Nemeth D, Limb R. Pain relief following day case laparoscopic tubal ligation with intra-peritoneal ropivacaine: a randomized double-blind control study. The Australian and New Zealand Journal Obstetrics and Gynecology. 2000; 40: 434–437.

[26] Goldstein A, Grimault P, Henique A, Keller M, Fortin A, Darai E. Preventing postoperative pain by local anesthetic instillation after laparoscopic gynecologic surgery: a placebo-controlled comparison of bupivacaine and ropivacaine. Anaesthesia and Anaesthesia. 2000; 91: 403–407.

[27] Kaufman Y, Hirsch I, Ostrovsky L, Klein O, Shnider I, Khoury E, Pisov R, et al. Pain relief by continuous intraperitoneal nebulisation of ropivacaine during gynecologic laparoscopic surgery—a randomised study and review of the literature. Journal of Minimally Invasive Gynecology. 2008; 15: 554–558.

[28] Scott DB, Lee A, Fagan D, Bowler GM, Bloomfield P, Lundr R. Acute toxicity of ropivacaine compared with that of bupivacaine. Anaesthesia and Anaesthesia. 1989; 69: 563–569.

[29] Knudsen K, Beckman Suurkula M, Blomberg S, Sjövall J, Edvardsen N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. British Journal of Anaesthesia. 1997; 78: 507–514.

[30] Markham A, Faulds D. Ropivacaine: A review of its pharmacology and therapeutic use in regional anaesthesia. Drugs. 1996; 52: 429–449.

[31] Jyoti K, Sharan R, Singh M, Kataria AP, Jarawel V, Kadian R. Intraplateal instillation of bupivacaine and ropivacaine for post-operative analgesia in laparoscopic cholecystectomy. Anaesthesia: Essays and Researches. 2018; 12: 377–380.

[32] Das NT, Deshpande C. Effects of intraperitoneal local anaesthetics bupivacaine and ropivacaine versus placebo on postoperative pain after laparoscopic cholecystectomy: a randomised double blind study. Journal of Clinical and Diagnostic Research. 2017; 11: UC08–UC12.

[33] Kucuk C, Kadiogullari N, Canoler O, Savli S. A placebo-controlled comparison of bupivacaine and ropivacaine instillation for preventing postoperative pain after laparoscopic cholecystectomy. Surgery Today. 2007; 17: 396–400.

[34] Labaille T, Mazoit JX, Paqueron X, Franco D, Benhamou D. The clinical efficacy and pharmacokinetics of intraperitoneal ropivacaine for laparoscopic cholecystectomy. Anaesthesia and Anaesthesia. 2002; 94: 100–105.

[35] Kallalhe K, Sannour T, Vather R, Taylor M, Stapelberg F, Hill AG. Systemic levels of local anaesthetic after intra-peritoneal application—a systematic review. Anaesthesia and Intensive Care. 2010; 38: 623–638.

[36] Allegri M, Ornaghi M, Ferland CE, Bugada D, Mehanghi Y, Calcinati S, et al. Peritoneal nebulization of ropivacaine during laparoscopic cholecystectomy: dose finding and pharmacokinetic study. Pain Research & Management. 2018; 2017: 4260702.

[37] Jahromi SA, Valami SM, Yaghoubi S. Determining the effect of intraperitoneal pethidine on postoperative pain. Middle East Journal of Anaesthesiology. 2011; 21: 39–42.

[38] Wrigley LC, Howard FM, Gabel D. Transcervical or intraperitoneal analgesia for laparoscopic tubal sterilisation: a randomised controlled trial. Obstetrics and Gynecology. 2000; 96: 895–898.

[39] Andrews V, Wright JT, Zakaria F, Banerjee S, Ballard K. Continuous infusion of local anesthetic following laparoscopic hysterectomy—a randomised controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology. 2014; 121: 754–760.
[40] Yong L, Guang B. Intraperitoneal ropivacaine instillation versus no intraperitoneal ropivacaine instillation for laparoscopic cholecystectomy: a systematic review and meta-analysis. International Journal of Surgery. 2017; 44: 229–243.

[41] Marks JL, Ata B, Tulandi T. Systematic review and metaanalysis of intraperitoneal instillation of local anesthetics for reduction of pain after gynecologic laparoscopy. Journal of Minimally Invasive Gynecology. 2012; 19: 545–553.

[42] Kahokehr A, Sammour T, Srinivasa S, Hill AG. Systematic review and metaanalysis of intraperitoneal instillation of local anesthetics for reduction of pain after gynecologic laparoscopy. The British Journal of Surgery. 2011; 98: 29–36.

[43] Zmora O, Stolik-Dollberg O, Bar-Zakai B, Rosin D, Kuriansky J, Shabtai M, et al. Intraperitoneal bupivacaine does not attenuate pain following laparoscopic cholecystectomy. Journal of the Society of Laparoendoscopic Surgeons. 2000; 4: 301–304.

[44] Gupta M, Naithani U, Singariya G, Gupta S. Comparison of 0.25% ropivacaine for intraperitoneal instillation v/s rectus sheath block for postoperative pain relief following laparoscopic cholecystectomy: a prospective study. Journal of Clinical Diagnostic Research. 2016; 10: UC10–UC15.